Updating results

Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

In development [GID-TA10228] Expected publication date: TBC

Technology appraisal guidance In development

NBTXR-3 for treating soft tissue sarcoma [ID1050]

In development [GID-TA10226] Expected publication date: TBC

Technology appraisal guidance In development

Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Technology appraisal guidance In development

Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

In development [GID-TA10225] Expected publication date: TBC

Technology appraisal guidance In development

Subarachnoid haemorrhage due to ruptured aneurysms

In development [GID-NG10097] Expected publication date: 03 February 2021

NICE guideline In development

Dupilumab for treating severe asthma

In development [GID-TA10276] Expected publication date: 06 May 2020

Technology appraisal guidance In development

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Technology appraisal guidance In development

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma [ID1576]

In development [GID-TA10463] Expected publication date: 08 April 2020

Technology appraisal guidance In development

LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Technology appraisal guidance In development

Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Technology appraisal guidance In development

Chronic pain: assessment and management

In development [GID-NG10069] Expected publication date: 19 August 2020

NICE guideline In development

Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270

In development [GID-TA10211] Expected publication date: TBC

Technology appraisal guidance In development

Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

In development [GID-TA10210] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168

In development [GID-TA10208] Expected publication date: TBC

Technology appraisal guidance In development

Selumetinib for treating differentiated thyroid cancer ID1079

In development [GID-TA10207] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development

Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]

In development [GID-TAG415] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Technology appraisal guidance In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]

In development [GID-TA10119] Expected publication date: 01 July 2020

Technology appraisal guidance In development

Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Technology appraisal guidance In development

Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

In development [GID-TA10033] Expected publication date: TBC

Technology appraisal guidance In development

Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]

In development [GID-TAG431] Expected publication date: TBC

Technology appraisal guidance In development

Falls - faller's clinics [ID103]

In development [GID-TAG375] Expected publication date: TBC

Technology appraisal guidance In development

Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Technology appraisal guidance In development

Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Technology appraisal guidance In development

Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

In development [GID-TAG411] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]

In development [GID-TAG337] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (VTE) - ximelagatran [ID396]

In development [GID-TAG378] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma - bortezomib (consolidation therapy) [ID529]

In development [GID-TAG320] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]

In development [GID-TAG528] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]

In development [GID-TAG479] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

In development [GID-TAG435] Expected publication date: TBC

Technology appraisal guidance In development

Osteoporosis (postmenopausal women) - abaloparatide [ID882]

In development [GID-TA10071] Expected publication date: TBC

Technology appraisal guidance In development

Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer - intensity modulated radiotherapy [ID16]

In development [GID-TAG390] Expected publication date: TBC

Technology appraisal guidance In development

Obesity - lorcaserin [ID337]

In development [GID-TAG420] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (acute lymphoblastic) - erythrocyte encapsulated asparaginase [ID864]

In development [GID-TA10047] Expected publication date: TBC

Technology appraisal guidance In development

Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

In development [GID-TA10088] Expected publication date: 27 December 2017

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Technology appraisal guidance In development